We are live on ! Find out more
A

Abingworth Portfolio holdings

AUM $307M
1-Year Est. Return 93.47%
This Fund
S&P 500
This Quarter Est. Return
-25.89%
1 Year Est. Return
+93.47%
3 Year Est. Return
+184.38%
5 Year Est. Return
+342.7%
10 Year Est. Return
–
AUM
$151M
AUM Growth
-$56.3M
Cap. Flow
+$13.2M
Cap. Flow %
8.75%
Top 10 Hldgs %
96.37%
Holding
16
New
–
Increased
2
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$11.4M
2
TARA icon
Protara Therapeutics
TARA
+$1.76M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PSNL icon
1
Personalis
PSNL
$1.4B
$43.6M 28.95%
5,449,294
– –
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$849M
$30.8M 20.47%
1,203,135
– –
CRSP icon
3
CRISPR Therapeutics
CRSP
$4.63B
$22M 14.58%
519,198
– –
SLNO
4
DELISTED
Soleno Therapeutics
SLNO
$15.7M 10.41%
464,618
– –
XCUR icon
5
Exicure
XCUR
$12M
$10.2M 6.76%
46,513
– –
SRRA
6
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$8.59M 5.7%
876,541
+871,124
+16,081% +$11.4M
SIEN
7
DELISTED
Sientra, Inc.
SIEN
$4.69M 3.11%
239,084
– –
VRNA
8
DELISTED
Verona Pharma
VRNA
$3.72M 2.47%
901,943
– –
PRTK
9
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$3.24M 2.15%
1,041,131
– –
MTEM
10
DELISTED
Molecular Templates, Inc.
MTEM
$2.64M 1.75%
13,333
– –
TARA icon
11
Protara Therapeutics
TARA
$229M
$2.62M 1.74%
113,919
+60,306
+112% +$1.76M
CHMA
12
DELISTED
Chiasma, Inc. Common Stock
CHMA
$1.35M 0.89%
370,671
– –
SYRE icon
13
Spyre Therapeutics
SYRE
$8.45B
$1.1M 0.73%
9,620
– –
OBSV
14
DELISTED
ObsEva SA Ordinary Shares
OBSV
$210K 0.14%
87,999
– –
CBAY
15
DELISTED
Cymabay Therapeutics
CBAY
$191K 0.13%
131,036
– –
OCGN icon
16
Ocugen
OCGN
$450M
$2K ﹤0.01%
7,111
– –

Similar funds

AAM
Arabesque Asset Management London, United Kingdom $296M AUM 15.19% 1-Year Est. Return
EP
Equius Partners Novato, California $324M AUM 8.27% 1-Year Est. Return
LDFR
Lehman & Derafelo Financial Resources Media, Pennsylvania $337M AUM 8.16% 1-Year Est. Return
MPAM
Monarch Partners Asset Management Boston, Massachusetts $339M AUM 2.52% 1-Year Est. Return
MAG
Mass Ave Global New York $342M AUM 20.58% 1-Year Est. Return
CDIA
Capital Directions Investment Advisors Atlanta, Georgia $268M AUM 20.15% 1-Year Est. Return
GTCM
Gyon Technologies Capital Management Denville, New Jersey $267M AUM 11.62% 1-Year Est. Return
ACMV
August Capital Management VII Palo Alto, California $265M AUM 26.86% 1-Year Est. Return

Abingworth's Q1 2020 Portfolio in Review

As of Q1 2020, Abingworth held 16 positions worth $151M, down 27% from $207M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

Abingworth deployed $13.2M of net new capital in Q1 2020, adding to 2 existing holdings.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Abingworth added most to Sierra Oncology, Inc. Common Stock in Q1 2020, an estimated $11.4M increase.
  • Abingworth's ten largest holdings make up 96% of its $151M portfolio in Q1 2020.
  • Abingworth opened 0 new positions and closed 0 in Q1 2020.
  • Abingworth's portfolio value fell 27% quarter-over-quarter to $151M.

Based on Abingworth's 13F filing for Q1 2020, filed 14 May 2020.